📊 Backtest📒 Journal Updated 29/09/2026
← 🔥 Turbo
📐 Simulate Position
STALE?Report written 62 days ago · at $1.62entry levels may be stale — re-check before acting

BIVI

MoonshotSMALL CAP
BioVie Inc. · NASDAQ · Healthcare / Biotechnology (Neurology)
$1.62
▲ 6.58%
MCap $12.2M
Self-fetched Aug 3, 2026 close: $1.62, +6.58% on the day. 52-week range $1.06–$6.15 (updated range vs the Jul 22 report's $8.84 high). Up from $1.29 on Jul 21, but the move looks like pre-catalyst positioning, not a fundamental re-rate — a much larger dilution event than last time is actively pending.
BusinessClinical-stage neuro biotech · bezisterim (NE3107) Phase 2 topline data due imminently for Long COVID (ADDRESS-LC) and Parkinson's (SUNRISE-PD) — nano-cap now racing a going-concern cash crunch AND an active 56M-share best-efforts offering set to resolve in the same window as the data
Thesis

Neither binary readout has happened yet — ADDRESS-LC (Long COVID) and SUNRISE-PD (Parkinson's) topline data are both still pending, targeted for Q3 2026 (ADDRESS-LC 'late summer'), so the core catalyst thesis from the Jul 22 report is intact and now closer. But the financial picture has deteriorated materially: cash fell from $20.5M (Dec 31, 2025) to $13.1M (Mar 31, 2026) — a burn of ~$7.4M in one quarter, faster than previously modeled — and BioVie filed a best-efforts S-1 on Jul 17, 2026 (amended Jul 31) registering up to 56,390,977 new shares (roughly 7-8x the current ~7.5M shares outstanding) that must complete or lapse by Sep 30, 2026 — the SAME window as the data. ⚠️ SURVIVAL: this is a materially bigger dilution risk than 13 days ago, not a smaller one — BioVie's own stock fell 43% in a single day (Aug 8, 2025) on a much smaller $12M offering, and this new one dwarfs it. Still included because the binary data catalyst is real, near, and analyst-backed (2-analyst average target $5.26, +225%), and because a survival flag is disclosure, not an automatic cut — but position sizing must assume the share count could balloon before the data even reads out. Max 2% position, no exceptions.

📝 Primary Verdict · Core Holding
SPECULATIVEMoonshot

Moonshot — tiny position only, sized for total loss. The binary data catalyst is real and closer than 13 days ago, but an active best-efforts offering for up to 56.4M shares (vs ~7.5M outstanding) is the dominant near-term risk and could move the stock before the data does.

81
score / 100 ⓘ
⚡ Catalyst
🧠 ADDRESS-LC Phase 2 Topline (Long COVID)~4 WEEKS

Topline results for bezisterim in Long COVID neurological symptoms (~200 patients, DoW-funded), following full enrollment announced May 26, 2026. Still pending as of Aug 4, 2026.

Late Summer 2026
🧬 SUNRISE-PD Phase 2 Topline (Parkinson's Disease)BY SEP 30

Bezisterim's early-stage Parkinson's trial completed its last patient visit May 18, 2026. Topline data still pending, targeted for Q3 2026 (by Sep 30).

Q3 2026
💰 Active Best-Efforts Offering Resolution (up to 56.4M shares)ACTIVE NOW

BioVie filed a best-efforts S-1 (Jul 17, 2026; amended Jul 31) to sell up to 56,390,977 shares (or equivalent pre-funded warrants) at an assumed $1.33/share — vs ~7.5M shares outstanding today. No minimum required; terminates Sep 30, 2026 if not completed sooner. This is a live, unresolved dilution overhang set to land in the same window as both data readouts.

By Sep 30, 2026
🎯 Entry Point
Entry 1
$1.62
Current price — pre-data AND pre-offering-resolution, both unresolvedNow (small)
Entry 2PREFERRED
$1.1–1.3
Likely zone if the pending offering prices at/near its $1.33 assumed level — best R/R if the raise clears before dataIf dips on offering news
Entry 3
$0.75
Deep capitulation — offering prices at a steep discount or broad biotech selloff, still ahead of dataDeep dip only
✅ Take Profit
TP1
Base — mixed/inconclusive data, market gives partial credit net of dilution
$2.27
+40.1%
TP2
Bull — one of the two readouts (ADDRESS-LC or SUNRISE-PD) is clearly positive
$4.05
+150%
TP3 🌙
Moon — both readouts positive, hits 2-analyst consensus target
$5.26
+225%
🔴 Stop Loss
Tight Stop
Below the 52-week low ($1.06) — thesis-neutral pre-data but a real warning sign given the active offering
$1
-38.3%
Hard Stop
Post-offering-crash / clearly negative readout / going-concern crisis territory
$0.6
-63%
Risk / Reward
From Entry 2 mid ($1.20) tight stop vs TP2
14.3 : 1
⚠ Asymmetric ✅ on paper, but this is a going-concern nano-cap with an active 7-8x dilution offering pending — 2% max position, no exceptions
📅 Estimate Date
FY2026 Annual Report / Cash Update
First real-time read on cash since Mar 31 ($13.1M) and on the status of the pending 56.4M-share offering
Aug 14, 2026
Cash burn + offering status
ADDRESS-LC Topline (Long COVID)
Binary readout — the primary near-term catalyst
Late Summer 2026
Positive/negative on primary endpoint
SUNRISE-PD Data (Parkinson's)
Trial completed May 2026, data analysis underway
Q3 2026 (by Sep 30)
Second binary shot in the same window
Best-Efforts Offering Deadline
Up to 56.39M shares must price/complete or the registration lapses
Sep 30, 2026
Dilution event or lapse
📈 Possible Up % — Scenario Spread
Bear
-55%
$0.73
Base
+40%
$2.27
Bull
+150%
$4.05
Moon
+225%
$5.26
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed held at 3.50-3.75% on Jul 29, 2026 with 3 hawkish dissents favoring a hike — rate-hike tail risk into year-end hasn't gone away.
Inflation
Core PCE still 3.3% YoY, well above the 2% target — the 10-year yield remaining elevated makes any dilutive equity raise from a going-concern nano-cap more expensive.
Sector Impact
Binary Phase 2 data outcomes are largely macro-independent in direction, but BIVI's active 56.4M-share offering will price worse into a high-rate, risk-off tape than into a rally — macro conditions directly affect how much dilution existing holders eat.
Summary
MEDIUM for the catalyst itself, HIGH for the financing risk — nothing about the Jul 29 FOMC changes whether the Phase 2 data reads out positive or negative, but a hawkish macro backdrop makes the pending best-efforts offering more punishing for existing shareholders.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (2 analysts, Strong Buy)
Buy$5.26+225%
Brookline Capital Markets (high-end)
Buy$12+641%
current price $1.62
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

FPRX✅ Goodhistorical
+349%
in 1 day
Five Prime Therapeutics — positive mid-stage combination cancer therapy data
Closest same-genre precedent for a small-cap binary Phase 2 win driving an outsized single-day move — directly relevant to BIVI's ADDRESS-LC/SUNRISE-PD setup.
BIVI❌ BadAug 2025
-43%
in 1 day
BioVie priced a $12M public offering of units at $2.00/share
Same-company, same-mechanism precedent for dilution risk — a much smaller offering than the current one already crushed the stock in a single session.
BIVI❌ Bad2025-2026
-83%
in 365 days
52-week high-to-low decline amid going-concern disclosure and repeated capital raises
Shows the full downside this stock has already realized on financing/sentiment risk even before either current Phase 2 readout has landed.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-35% / -50%) only when trading the earnings spot — not for the core holding (use the -38.3% / -63% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
-10% to +5% pre-event, with added downside risk from the offering resolving before data doesminimal to negative pre-event drift; further suppressed by the pending 56.4M-share offering

Clinical-stage nano-caps with binary Phase 2 data typically see limited pre-readout runup and trade sideways-to-down into the event — and BIVI's setup is worse than the norm because an active dilutive offering is competing for the stock's direction ahead of the data.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +150%
range: +50% to +349%· historical small-cap Phase 2 precedent (FPRX)
Small-cap biotechs on positive mid-stage data have posted moves in this range — Five Prime Therapeutics (FPRX) jumped as much as 349% on positive mid-stage combination-therapy data, the closest same-genre precedent for a nano-cap binary Phase 2 win.
❌ Catalyst Missavg -45%
range: -30% to -70%· Aug 8, 2025 (BIVI's own dilutive-offering crash)
BIVI's own stock fell 43% in a single day (Aug 8, 2025) after pricing a $12M public offering — direct, same-company precedent for how hard a dilutive raise hits this stock, now amplified by a much larger pending offering (up to 56.4M shares) landing in the same window as the data.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio

Going-concern nano-cap with two binary catalysts plus an active 7-8x dilution offering pending before either readout — 2% caps the loss to a tolerable level while keeping exposure to the +225% consensus upside if a readout hits before or despite the raise.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-35%($1.05)
Below the 52-week low ahead of data — thesis-neutral but a real warning sign of financing stress or a poorly-received offering
After Catalyst (Bad Result)-50%
A clearly negative readout on both trials, or the offering pricing at a severe discount with a large raise, ends the thesis — exit
📎 Sources

Generated 2026-08-04 · Not financial advice